PHARMACOTHERAPY FOR PRIMARY CARE
Hilton Head Marriott Resort & SpaSOUTH CAROLINA, USA Visit the Venue to read more
This conference is designed to provide primary care practitioners with up-to-date, evidence-based information on commonly encountered pharmacotherapy medical issues, while suggesting pragmatic approaches to clinical management. The discussion-based format of the conference will encourage audience participation through dynamic lectures, case-based studies, and hands-on workshops. Keynote speakers will present and critically assess recent advancements and industry updates in Pharmacotherapy for Primary Care, with the goal of enhancing the knowledge base and core competence of attendees. The successful completion of this interactive program should improve attendees’ confidence in diagnosing, treating, and prescribing the most effective courses of treatment, with the ultimate goal of improving patient outcomes.
Family Physicians and all Physicians and other Healthcare Professionals interested in learning more about Pharmacotherapy issues.
Our presenting national faculty speakers made it their professional goals to enhance the training of primary care healthcare professionals. This Continuing Medical Education program promises to help learn the most current, best medicine, and techniques for making the diagnosis easier and quicker during a 20 minute office visit.
Topics and Objectives
Making a Difference in Cardiovascular Disease: Update on Lipids - 2013 ACC/AHA, 2014 NLA, and 2014 VA/DOD Expert Panels
Objectives: 1) Describe the new ACC/AHA; NLA and VA/DOD Lipid Guidelines and the evidence on which they are based 2) Discuss the benefits and risks associated with the use of HMG-CoA reductase inhibitors (statins) either alone or in combination with other agents (to include potential adverse effects and drug-drug interactions) 3) Describe the recent lipid trials which have been published and or presented after the release of NCEP ATP-III to include the Heart Protection Study, CARDS, TNT, FIELD, PROVE-IT, SEARCH, AIM-HIGH, ACCORD-Lipid, HPS-2 THRIVE and IMPROVE-IT ) 4) Describe the potential benefits and risks of the currently available non-statin medications for the management of patients with dyslipidemia (bile acid sequestrants, niacin, fibrates, ezetimibe, fish oil and cholesterol ester transfer protein (CETP) inhibitors (investigational) 5) Describe the mechanism, effects and clinical use of the two new PCSK-9 inhibitors evolocumab and alirocumab
Strategies for Treating Patients with Hypertension to Goal: JNC-8, ASH and UK – NICE Guidelines and potential implications based upon the SPRINT Trial
Objectives: 1) Discuss the importance of systolic blood pressure vs. diastolic blood pressure in the risk of cardiovascular events and the benefits of blood pressure lowering and what are the best goal BP levels given new evidence from ACCOMPLISH, Kaiser and the Sprint Trial 2) Describe the current evidence-based strategies for the management of patients with hypertension including the JNC-8, ASH and the UK-NICE evidence-based guidelines 3) Describe the data that the Committee (JNC-8) and other National Guidelines used in deciding upon the compelling indications for specific antihypertensive agents in treating selected patients 4) Recommend a specific evidence-based treatment regimen for a patient with hypertension and concurrent conditions
Evidence Based Management of Patients with Type 2 Diabetes Mellitus
Objectives: 1) Describe the relationship between obesity and the risk of Type 2 diabetes and the benefits of lifestyle modification (IE diet and exercise) in reducing the risk and helping to prevent and manage patients with Type 2 diabetes 2) Describe the current 2016 ADA Standards of Medical Care for the diagnosis and management of diabetes mellitus and the AACE/ACE Comprehensive Diabetes management Algorithm 2015 and the evidence on which they are based 3) Discuss the appropriate use of evidence-based and cost effective therapies in the management of patients with Type 2 diabetes mellitus 4) Describe the benefits of treating glucose, blood pressure and lipids in patients with Type 2 diabetes
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
Leslie Burk , MCE Conferences
Leslie Burk , MCE Conferences